Loading..

Ligand Pharmaceuticals Incorporated (LGND) Report Analysis

Corporate Events

Neutral

Ligand Pharmaceuticals Incorporated has filed a...

2022-06-13 00:00:00

Ligand Pharmaceuticals Incorporated has filed a Shelf Registration in the amount of $82.4616 million. Security Name: Common Stock Securiti...

Neutral

Tranche Update on Ligand Pharmaceuticals Incorp...

2022-05-09 16:09:00

From January 1, 2022 to March 31, 2022, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has compl...

Neutral

Ligand Pharmaceuticals Incorporated Reaffirms R...

2022-05-04 20:01:00

Ligand Pharmaceuticals Incorporated reaffirmed revenue guidance for the year 2022. For the year, the company expected royalties of $55 million...

Neutral

Ligand Pharmaceuticals Incorporated, Annual Gen...

2022-04-22 20:11:00

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 10, 2022, at 08:30 Pacific Standard Time. Agenda: To elect a board of directo...

Neutral

Ligand Pharmaceuticals Incorporated - Sharehold...

2022-04-22 20:11:00

AGM

Neutral

Ligand Pharmaceuticals Incorporated, Q1 2022 Ea...

2022-04-19 20:01:00

Ligand Pharmaceuticals Incorporated, Q1 2022 Earnings Call, May 04, 2022

Neutral

Ligand Pharmaceuticals Incorporated to Report Q...

2022-04-19 20:01:00

Ligand Pharmaceuticals Incorporated announced that they will report Q1, 2022 results After-Market on May 04, 2022

Neutral

Tranche Update on Ligand Pharmaceuticals Incorp...

2022-02-28 17:28:00

From October 1, 2021 to December 31, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has co...

Neutral

Ligand Pharmaceuticals Incorporated Reaffirms F...

2021-11-09 21:02:00

Ligand Pharmaceuticals Incorporated reaffirmed financial guidance for 2021. The company expects full-year 2021 total revenues to be between $2...

Neutral

Ligand Pharmaceuticals Incorporated to Report Q...

2021-10-26 20:01:00

Ligand Pharmaceuticals Incorporated announced that they will report Q3, 2021 results After-Market on Nov 09, 2021

Neutral

Ligand Pharmaceuticals Incorporated, Q3 2021 Ea...

2021-10-26 20:01:00

Ligand Pharmaceuticals Incorporated, Q3 2021 Earnings Call, Nov 09, 2021

Neutral

Ligand Pharmaceuticals Incorporated and China R...

2021-10-21 13:00:00

Ligand Pharmaceuticals Incorporated announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co...

Neutral

Ligand Pharmaceuticals Incorporated Presents at...

2021-10-06 12:38:00

Ligand Pharmaceuticals Incorporated Presents at Antibody Engineering & Therapeutics US, Dec-15-2021 11:00 AM. Venue: Marriott Marquis San Dieg...

Positive

Ligand Pharmaceuticals Incorporated(NasdaqGM:LG...

2021-09-07 00:00:00

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to S&P 600

Positive

Ligand Pharmaceuticals Incorporated(NasdaqGM:LG...

2021-09-07 00:00:00

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to S&P 600 Health Care (Sector)

Negative

Ligand Pharmaceuticals Incorporated(NasdaqGM:LG...

2021-08-31 00:00:00

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from S&P 400

Negative

Ligand Pharmaceuticals Incorporated(NasdaqGM:LG...

2021-08-31 00:00:00

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from S&P 400 Health Care (Sector)

Negative

Ligand Pharmaceuticals Incorporated(NasdaqGM:LG...

2021-08-31 00:00:00

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from S&P 400 - Biotechnology (Industry)

Neutral

Tranche Update on Ligand Pharmaceuticals Incorp...

2021-08-03 10:11:00

From April 1, 2021 to June 30, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has complete...

Negative

Ligand Pharmaceuticals Incorporated Provides Ea...

2021-07-29 20:01:00

Ligand Pharmaceuticals Incorporated provided earnings guidance for the fiscal year 2021. For the year, Ligand now expects full-year 2021 total...

Positive

Ligand’s Partner Merck Receives FDA Approval fo...

2021-07-19 12:00:00

Ligand Pharmaceuticals Incorporated announced that its partner Merck has received approval from the U.S. Food and Drug Administration (FDA) fo...

Neutral

Ligand Pharmaceuticals Incorporated to Report Q...

2021-07-16 13:00:00

Ligand Pharmaceuticals Incorporated announced that they will report Q2, 2021 results After-Market on Jul 29, 2021

Neutral

Ligand Pharmaceuticals Incorporated, Q2 2021 Ea...

2021-07-16 13:00:00

Ligand Pharmaceuticals Incorporated, Q2 2021 Earnings Call, Jul 29, 2021

Negative

Ligand Pharmaceuticals Incorporated Appoints Dr...

2021-07-14 20:01:00

Ligand Pharmaceuticals Incorporated announced the appointment of Jennifer Cochran, Ph.D. to the company's Board of Directors. Dr. Cochran is t...

Neutral

Ligand Pharmaceuticals Incorporated has filed a Shelf Registration in the amount of $82.4616 million.

2022-06-13 00:00:00

Ligand Pharmaceuticals Incorporated has filed a Shelf Registration in the amount of $82.4616 million. Security Name: Common Stock Securities Offered: 1,040,000 Transaction Features: ESOP Related Offering

Neutral

Tranche Update on Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND)'s Equity Buyback Plan announced on September 12, 2019.

2022-05-09 16:09:00

From January 1, 2022 to March 31, 2022, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 1,695,007 shares, representing 9.9% for $159.95 million under the buyback announced on September 12, 2019.

Neutral

Ligand Pharmaceuticals Incorporated Reaffirms Revenue Guidance for the Year 2022

2022-05-04 20:01:00

Ligand Pharmaceuticals Incorporated reaffirmed revenue guidance for the year 2022. For the year, the company expected royalties of $55 million to $60 million, Captisol sales of $40 million to $50 million and contract revenue of $52 million to $62 million. These revenue components result in total revenue of $147 million to $172 million for the combined business. Ligand expects that $35 million to $45 million of revenue will be attributable to OmniAb, principally in the contract revenue line.

Neutral

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 10, 2022

2022-04-22 20:11:00

Ligand Pharmaceuticals Incorporated, Annual General Meeting, Jun 10, 2022, at 08:30 Pacific Standard Time. Agenda: To elect a board of directors for the forthcoming year. The company's board of directors has nominated the following ten persons, each to serve for a one year term to expire at the 2023 annual meeting of stockholders: Jason Aryeh, Sarah Boyce, Jennifer Cochran, Todd Davis, Nancy Gray, John Higgins, John Kozarich, John LaMattina, Sunil Patel and Stephen Sabba; to ratify the selection of Ernst & Young LLP as independent registered accounting firm for the fiscal year ending December 31, 2022; and to consider other matters.

Neutral

Ligand Pharmaceuticals Incorporated - Shareholder/Analyst Call

2022-04-22 20:11:00

AGM

Neutral

Ligand Pharmaceuticals Incorporated, Q1 2022 Earnings Call, May 04, 2022

2022-04-19 20:01:00

Ligand Pharmaceuticals Incorporated, Q1 2022 Earnings Call, May 04, 2022

Neutral

Ligand Pharmaceuticals Incorporated to Report Q1, 2022 Results on May 04, 2022

2022-04-19 20:01:00

Ligand Pharmaceuticals Incorporated announced that they will report Q1, 2022 results After-Market on May 04, 2022

Neutral

Tranche Update on Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND)'s Equity Buyback Plan announced on September 12, 2019.

2022-02-28 17:28:00

From October 1, 2021 to December 31, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 1,695,007 shares, representing 9.9% for $159.95 million under the buyback announced on September 12, 2019.

Neutral

Ligand Pharmaceuticals Incorporated Reaffirms Financial Guidance for 2021

2021-11-09 21:02:00

Ligand Pharmaceuticals Incorporated reaffirmed financial guidance for 2021. The company expects full-year 2021 total revenues to be between $265 million and $275 million.

Neutral

Ligand Pharmaceuticals Incorporated to Report Q3, 2021 Results on Nov 09, 2021

2021-10-26 20:01:00

Ligand Pharmaceuticals Incorporated announced that they will report Q3, 2021 results After-Market on Nov 09, 2021

Neutral

Ligand Pharmaceuticals Incorporated, Q3 2021 Earnings Call, Nov 09, 2021

2021-10-26 20:01:00

Ligand Pharmaceuticals Incorporated, Q3 2021 Earnings Call, Nov 09, 2021

Neutral

Ligand Pharmaceuticals Incorporated and China Resources Double-Crane Pharmaceutical Co.,Ltd. Enters into Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™

2021-10-21 13:00:00

Ligand Pharmaceuticals Incorporated announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co. Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligand’s BEPro technology. Ligand will receive an upfront payment in respect of the collaboration, and if the program advances, clinical and regulatory milestone payments, and tiered royalties on net sales. CRDC will be responsible for all costs related to the program. BEPro is a proprietary prodrug technology that is specifically applicable to nucleotides and nucleotide analogs for the development of compounds with improved product profiles. Ligand has generated preclinical pharmacokinetics data showing its oral BEPro-enabled COVID-19 antivirals to have a favorable blood concentration profile and generate lower levels of active nucleotide in the kidney, a potential site for toxicity, than other oral and intravenous comparators. Ligand has filed multiple patents globally on the BEPro technology and potential antiviral compounds.

Neutral

Ligand Pharmaceuticals Incorporated Presents at Antibody Engineering & Therapeutics US, Dec-15-2021 11:00 AM

2021-10-06 12:38:00

Ligand Pharmaceuticals Incorporated Presents at Antibody Engineering & Therapeutics US, Dec-15-2021 11:00 AM. Venue: Marriott Marquis San Diego, San Diego, California, United States. Speakers: Phil Leighton, Senior Director of Molecular Biology.

Positive

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to S&P 600

2021-09-07 00:00:00

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to S&P 600

Positive

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to S&P 600 Health Care (Sector)

2021-09-07 00:00:00

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to S&P 600 Health Care (Sector)

Negative

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from S&P 400

2021-08-31 00:00:00

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from S&P 400

Negative

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from S&P 400 Health Care (Sector)

2021-08-31 00:00:00

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from S&P 400 Health Care (Sector)

Negative

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from S&P 400 - Biotechnology (Industry)

2021-08-31 00:00:00

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from S&P 400 - Biotechnology (Industry)

Neutral

Tranche Update on Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND)'s Equity Buyback Plan announced on September 12, 2019.

2021-08-03 10:11:00

From April 1, 2021 to June 30, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 1,695,007 shares, representing 9.9% for $159.95 million under the buyback announced on September 12, 2019.

Negative

Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Fiscal Year 2021

2021-07-29 20:01:00

Ligand Pharmaceuticals Incorporated provided earnings guidance for the fiscal year 2021. For the year, Ligand now expects full-year 2021 total revenues to be between $265 million and $275 million, and adjusted earnings per diluted share to be between $5.80 and $6.05. This compares with previous 2021 guidance for total revenues of $291 million and adjusted earnings per diluted share of $6.15.

Positive

Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes

2021-07-19 12:00:00

Ligand Pharmaceuticals Incorporated announced that its partner Merck has received approval from the U.S. Food and Drug Administration (FDA) for VAXNEUVANCETM, also known as V114, for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older. VAXNEUVANCE is a 15-valent pneumococcal vaccine utilizing Ligand’s CRM197 vaccine carrier protein, which is produced using the patent-protected Pelican Expression Technology™ platform. Under the terms of the licensing agreement with Merck, Ligand earned a $2 million milestone payment upon FDA approval of VAXNEUVANCE and is entitled to a low-single-digit royalty on net product sales. Merck plans to submit a supplemental regulatory licensure application with the FDA later this year for the use of VAXNEUVANCE in children.

Neutral

Ligand Pharmaceuticals Incorporated to Report Q2, 2021 Results on Jul 29, 2021

2021-07-16 13:00:00

Ligand Pharmaceuticals Incorporated announced that they will report Q2, 2021 results After-Market on Jul 29, 2021

Neutral

Ligand Pharmaceuticals Incorporated, Q2 2021 Earnings Call, Jul 29, 2021

2021-07-16 13:00:00

Ligand Pharmaceuticals Incorporated, Q2 2021 Earnings Call, Jul 29, 2021

Negative

Ligand Pharmaceuticals Incorporated Appoints Dr. Jennifer Cochran to its Board of Directors

2021-07-14 20:01:00

Ligand Pharmaceuticals Incorporated announced the appointment of Jennifer Cochran, Ph.D. to the company's Board of Directors. Dr. Cochran is the Shriram Chair of the Department of Bioengineering at Stanford University, where she also is a professor of bioengineering and (by courtesy) of chemical engineering and a member of the cancer biology, biophysics and immunology programs. Dr. Cochran has been with Stanford since 2005, with a leave of absence from 2015 to 2017 to focus on entrepreneurial pursuits. From 2015 to 2020 she served as Chief Scientist of Lagunita Biosciences, a healthcare investment company and incubator, and was co-founder and Director of xCella Biosciences, where she also served as President from 2015 to 2017. In 2020 she co-founded Red Tree Venture Capital, a life sciences investment fund where she serves as Chief Scientific Advisor.

Fundamental Summary

Ligand Pharmaceuticals published its Q1 report on 2022-05-09 with positive results, but no significant factors particularly remarkable relative to its peers. We do believe, though, that macro-related market conditions will influence their performance more significantly than its individual results. Therefore, Ligand Pharmaceuticals received an overall score of 65, translating into a HOLD ranking.

Ligand Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 45.69 million compared to USD 55.15 million a year ago. Net loss was USD 15.39 million compared to net income of USD 18.11 million a year ago. Basic loss per share from continuing operations was USD 0.91 compared to basic earnings per share from continuing operations of USD 1.1 a year ago. Diluted loss per share from continuing operations was USD 0.91 compared to diluted earnings per share from continuing operations of USD 1.05 a year ago.

Business Description

Ligand Pharmaceuticals, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company’s partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

Sector Overview

Ligand Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Ligand Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 1,105.2 -14.8% 63
Liabilities 312.0 -34.5% 75
Price to Book 1.9 -40.1% 52
Cash & Equivalents 15.0 -23.2% 49
Equity 793.2 -3.4% 61
EBITDA 81.5 -14.1% 53
Total Revenues 267.7 -3.4% 92
Parameter Value Change Score
Return on Equity 3.1 -58.8% 78
Net Cashflow -17.2 39.5% 86
Capital Expenditure -10.2 -16.8% 51
Asset Turnover 0.2 7.0% 78
Free Cashflow 6.6 55.5% 93

* All values are TTM

The below chart reflects Ligand Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Ligand Pharmaceuticals's peer average final assessment score stands on 72.0, Ligand Pharmaceuticals's score is 65.

  •  LGND
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 0 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 1 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 2 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 3 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 4 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 5 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 6 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 7 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 8 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 9 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 10 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 11 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 12 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 13 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 15 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 16 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 17 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 18 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 19 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 20 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 22 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 23 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 24 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 26 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 27 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 28 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 30 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 31 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 32 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 33 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 34 1
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 35 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 36 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 37 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 39 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 40 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 41 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 42 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 43 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 44 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 46 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 47 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 48 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 50 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 54 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 55 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 57 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 58 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 59 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 60 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 61 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 62 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 65 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 66 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 69 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 70 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 73 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 74 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 75 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 76 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 77 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 80 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 81 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 82 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 83 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 84 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 85 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 87 1
Heron Therapeutics, Inc. 314.6M 58 62 71
Underperform
59
59 88 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 89 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 90 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 91 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 92 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 93 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 94 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 95 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Ligand Pharmaceuticals's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Ligand Pharmaceuticals's stock doesn't strongly signal being overbought or oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 52.

Bearish 52
Close Price 87.21
52W Low 74.52
52W High 165.85
5D MA 86.94
50D MA 87.14
200D MA 120.45
MACD -0.31
RSI 57.73
STOCH 82.46

Balance Sheet Analysis

Ligand Pharmaceuticals's recently published balance sheet showed overall, underwhelming numbers. Both Cash & Equivalents and Book Value Factors were particularly concerning. Ligand Pharmaceuticals did a poor job related to managing cash and cash equivalents this period, which stood at 15.0, representing a -23.2% change from the previous filing. This performance is significantly less impressive than its peers and competitors. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their cash and cash equivalents with a score of 49. Also, Ligand Pharmaceuticals publishes discouraging results related to book value factors in this report. As of the current filing, price to book ratio (P/B) was reported as 1.9, representing a -40.1% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Consequently, their book value factors movement received a grade of 52. However, we can draw some encouragement from Ligand Pharmaceuticals's momentum in Liabilities generation. Ligand Pharmaceuticals is doing a good job of keeping its liabilities under control and growing intelligently. At filing, their liabilities were 312.0, representing -34.5% change from the previous period. This performance is all interesting relative to their peers and suggests that their stock price has room to grow to reflect a higher intrinsic value. These results statistically lead to positive movement in stock prices, so we rated its liabilities movement component 75. Consequently, their balance sheet earned a rank of 56.

Parameter Value Change Score
Assets 1,105.2 -14.8% 63
Liabilities 312.0 -34.5% 75
Price to Book 1.9 -40.1% 52
Cash & Equivalents 15.0 -23.2% 49
Equity 793.2 -3.4% 61
* All values are TTM

The below chart describes Ligand Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Ligand Pharmaceuticals received a balance sheet score of 56, the average of its peers stands on 69.0.

  •  LGND
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 0 1
CureVac N.V. 2.6B 49 64 75 52 52 57 1 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 2 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 3 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 4 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 5 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 6 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 7 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 8 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 9 1
CareDx, Inc 1.2B 54 67 52 39 51 52 10 1
MannKind Corporation 957.2M 79 59 50 40 64 57 11 1
Merus N.V. 941.6M 59 68 50 83 81 70 12 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 14 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 15 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 16 1
Affimed N.V. 415.0M 56 66 63 56 47 54 17 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 18 1
AC Immune SA 299.8M 84 64 47 53 75 68 19 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 20 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 22 1
Amgen Inc. 130.1B 72 68 86 53 62 69 23 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 24 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 26 1
BioNTech SE 34.0B 75 69 64 97 73 75 27 1
Seagen Inc. 32.9B 59 68 55 43 66 61 28 1
Biogen Inc. 29.7B 57 72 92 50 76 76 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 30 1
Incyte Corporation 16.8B 71 72 95 82 79 83 31 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 32 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 33 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 34 1
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 35 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 36 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 37 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 38 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 39 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 40 1
Alkermes plc 5.0B 63 66 46 54 71 62 41 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 42 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 43 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 44 1
Natera, Inc. 3.6B 73 65 43 95 42 54 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 46 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 47 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 48 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 50 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 54 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 55 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 56 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 57 1
Vericel Corporation 1.1B 51 65 56 53 61 57 58 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 59 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 60 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 61 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 62 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 63 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 65 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 66 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 68 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 69 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 70 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 73 1
Geron Corporation 566.2M 69 72 37 59 62 60 74 1
Immatics N.V. 538.7M 56 70 84 95 73 76 75 1
Agenus Inc. 520.5M 73 62 37 55 60 54 76 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 77 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 80 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 81 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 82 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 83 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 84 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 85 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 87 1
Heron Therapeutics, Inc. 314.6M 84 65 48 43 58 58 88 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 89 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 90 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 91 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 92 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 93 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 94 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 95 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Ligand Pharmaceuticals appears likely to maintain its strong income statement metrics and momentum going forward. Ligand Pharmaceuticals did an excellent job managing its revenue efficiency this past period. Ligand Pharmaceuticals's revenue efficiency is 267.7 according to the metrics in the current filing, which represents a -3.4% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their industry-leading revenue efficiency makes a strong case for upward pressure on its's stock price. The company's revenue efficiency, therefore, received a grade of 92. Also, Ligand Pharmaceuticals's reported return on equity (ROE) ratio was 3.1, representing a change of -58.8%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. Consequently, their return factors received a grade of 78. That said, one metric, EBITDA, stood out as strongly negative. Ligand Pharmaceuticals's EBIDTA now sits at 81.5 and represents -14.1% change from the last reporting period. This parameter coud affect companies in the same industry and market capitalization by up to 24.4%. Ligand Pharmaceuticals appears to be headed in the wrong direction in terms of EBITDA momentum, likely due to insufficient capital controls and a weaker than expected overall financial performance. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their EBITDA a grade of 53. As the companie's management is doing an excellent job managing the critical metrics, the income statement was given a score of 69.

Parameter Value Change Score
EBITDA 81.5 -14.1% 53
Total Revenues 267.7 -3.4% 92
Return on Equity 3.1 -58.8% 78
* All values are TTM

The below chart describes Ligand Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Ligand Pharmaceuticals received a income statement score of 69 , the average of its peers stands on 72.0.

  •  LGND
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 0 1
CureVac N.V. 2.6B 45 83 71 74 1 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 2 1
Abgenix Inc. 2.1B 47 47 47 47 3 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 4 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 5 1
Xencor, Inc. 1.6B 42 94 52 79 6 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 7 1
Veracyte, Inc. 1.4B 45 63 57 55 8 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 9 1
CareDx, Inc 1.2B 61 44 82 50 10 1
MannKind Corporation 957.2M 95 48 56 61 11 1
Merus N.V. 941.6M 48 60 59 54 12 1
Amarin Corporation plc 734.5M 95 44 82 63 13 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 14 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 15 1
Radius Health, Inc. 499.8M 94 71 68 82 16 1
Affimed N.V. 415.0M 95 49 75 66 17 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 18 1
AC Immune SA 299.8M 83 61 65 70 19 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 20 1
Chimerix, Inc. 178.4M 99 50 62 65 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 22 1
Amgen Inc. 130.1B 74 75 64 78 23 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 24 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 26 1
BioNTech SE 34.0B 41 89 75 79 27 1
Seagen Inc. 32.9B 54 65 70 62 28 1
Biogen Inc. 29.7B 90 57 73 70 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 30 1
Incyte Corporation 16.8B 59 77 60 73 31 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 32 1
United Therapeutics Corporation 10.6B 57 91 54 82 33 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 34 1
Exact Sciences Corporation 7.2B 57 67 54 62 35 1
Exelixis, Inc. 6.7B 54 91 54 81 36 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 37 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 38 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 39 1
Ascendis Pharma A/S 5.2B 38 68 46 54 40 1
Alkermes plc 5.0B 69 55 81 62 41 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 42 1
Novavax, Inc. 4.0B 41 89 54 75 43 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 44 1
Natera, Inc. 3.6B 52 51 78 52 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 46 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 47 1
Insmed Incorporated 2.4B 51 58 73 57 48 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 50 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 54 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 55 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 56 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 57 1
Vericel Corporation 1.1B 76 44 82 56 58 1
IVERIC bio, Inc. 1.1B 84 58 79 70 59 1
FibroGen, Inc. 1.0B 48 74 63 67 60 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 61 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 62 1
ImmunoGen, Inc. 946.1M 40 73 71 64 63 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 65 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 66 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 68 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 69 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 70 1
CTI BioPharma Corp. 603.6M 84 50 62 59 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
AnaptysBio, Inc. 586.3M 97 50 77 68 73 1
Geron Corporation 566.2M 89 67 73 78 74 1
Immatics N.V. 538.7M 37 93 53 77 75 1
Agenus Inc. 520.5M 57 83 45 74 76 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 77 1
Vaxart, Inc. 440.0M 99 51 72 68 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
MiMedx Group, Inc. 391.5M 87 43 83 59 80 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 81 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 82 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 83 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 84 1
Zymeworks Inc. 324.7M 58 53 77 56 85 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 87 1
Heron Therapeutics, Inc. 314.6M 61 60 75 62 88 1
Silence Therapeutics plc 313.4M 83 64 69 72 89 1
Precigen, Inc. 299.1M 57 87 59 79 90 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 91 1
bluebird bio, Inc. 288.7M 99 91 61 96 92 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 93 1
MacroGenics, Inc. 184.6M 95 56 74 71 94 1
DermTech, Inc. 165.3M 49 48 78 52 95 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Ligand Pharmaceuticals appears likely to maintain its strong cash flow metrics and momentum going forward. Ligand Pharmaceuticals did a great job related to free cash flow this period, which stood at 6.6, representing a 55.5% change from the previous filing. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. Their free cash flow situation is all the more impressive relative to their peers and competitors. Therefore, its free cash flow movement earned a score of 93. Also, Ligand Pharmaceuticals's strong net cash flow numbers, which were -17.2 in this filing, showed a 39.5% change from the last period. This industry-leading net cash flow momentum should reinforce broader positive momentum for its's stock price going forward. Consequently, their net cash flow movement received a grade of 86. At the same time, one critical cash flow metric, Capital Expenditure, was notably weak. Ligand Pharmaceuticals's published capital expenditures (CapEx) numbers were discouraging and reflected management's unbalanced growth strategy. Ligand Pharmaceuticals recorded CapEx of -10.2, which represents a -16.8% change from the previous report. They appears to be headed in the wrong direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Therefore, their CapEx movement component earned a score of 51. Because the company's management is doing an excellent job managing these critical metrics, the cash flow was given a score of 84.

Parameter Value Change Score
Net Cashflow -17.2 39.5% 86
Capital Expenditure -10.2 -16.8% 51
Asset Turnover 0.2 7.0% 78
Free Cashflow 6.6 55.5% 93
* All values are TTM

The below chart describes Ligand Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Ligand Pharmaceuticals received a cash flow score of 84, the average of its peers stands on 72.0.

  •  LGND
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 0 1
CureVac N.V. 2.6B 87 80 90 70 90 1 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 2 1
Abgenix Inc. 2.1B 66 53 45 59 58 3 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 4 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 5 1
Xencor, Inc. 1.6B 96 95 70 95 98 6 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 7 1
Veracyte, Inc. 1.4B 90 95 46 46 82 8 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 9 1
CareDx, Inc 1.2B 98 84 40 50 86 10 1
MannKind Corporation 957.2M 77 56 43 37 66 11 1
Merus N.V. 941.6M 70 71 74 53 71 12 1
Amarin Corporation plc 734.5M 52 40 74 55 55 13 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 14 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 15 1
Radius Health, Inc. 499.8M 64 40 37 56 57 16 1
Affimed N.V. 415.0M 72 57 95 43 74 17 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 18 1
AC Immune SA 299.8M 66 77 79 63 68 19 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 20 1
Chimerix, Inc. 178.4M 80 84 95 47 83 21 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 22 1
Amgen Inc. 130.1B 80 74 67 74 81 23 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 24 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 25 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 26 1
BioNTech SE 34.0B 73 97 50 52 72 27 1
Seagen Inc. 32.9B 53 53 50 87 58 28 1
Biogen Inc. 29.7B 58 54 90 73 66 29 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 30 1
Incyte Corporation 16.8B 78 79 92 74 84 31 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 32 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 33 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 34 1
Exact Sciences Corporation 7.2B 53 45 80 46 56 35 1
Exelixis, Inc. 6.7B 79 90 89 83 87 36 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 37 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 38 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 39 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 40 1
Alkermes plc 5.0B 89 95 76 80 92 41 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 42 1
Novavax, Inc. 4.0B 62 38 63 54 60 43 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 44 1
Natera, Inc. 3.6B 52 54 56 84 58 45 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 46 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 47 1
Insmed Incorporated 2.4B 79 80 61 89 82 48 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 49 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 50 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 51 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 54 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 55 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 56 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 57 1
Vericel Corporation 1.1B 64 46 59 73 65 58 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 59 1
FibroGen, Inc. 1.0B 86 74 48 87 84 60 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 61 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 62 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 63 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 64 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 65 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 66 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 67 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 68 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 69 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 70 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 73 1
Geron Corporation 566.2M 78 68 49 81 77 74 1
Immatics N.V. 538.7M 82 95 56 99 86 75 1
Agenus Inc. 520.5M 57 43 52 77 58 76 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 77 1
Vaxart, Inc. 440.0M 72 56 53 38 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 80 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 81 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 82 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 83 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 84 1
Zymeworks Inc. 324.7M 52 65 45 83 57 85 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 86 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 87 1
Heron Therapeutics, Inc. 314.6M 66 74 61 84 71 88 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 89 1
Precigen, Inc. 299.1M 82 75 37 85 74 90 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 91 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 92 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 93 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 94 1
DermTech, Inc. 165.3M 60 51 45 86 58 95 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.